Session: SUN 199-233-Bone Biology
Poster Board SUN-214
Materials & Methods: Human osteoblasts (hFOB 1.19) were cultured and incubated in a medium with or without pioglitazone or rosiglitazone (5-20 μM). BSP, β-catanin, OPG, RANKL, FGF-23 (ELISA) and calcium and phosphate concentrations (colorimetric method) were measured.
Results: P and R inhibited BSP synthesis by 29.5% (p<0.028) and 26.6% (p<0.001), respectively. Calcium content was inhibited by 29.9% (p<0.001) and 23.1% and phosphate content was inhibited by 23.0% (p<0.001) and 29.6% (p<0.001), respectively by P and R. FGF-23 production was not significantly changed. However, at a concentration of 20 μM, P and R enhanced the FGF-23 production by 39% (p<0.047) and 109% (p<0.033), respectively. β-catanin was inhibited by P and R by 71.3% (p<0.001) and 50.8% (p<0.006) and OPG synthesis was inhibited by 70% (p<0.001) and 55.8% (p<0.001), respectively. Total RANKL production was not significantly affected.
Conclusion: TZDs inhibit BSP, β-catanin and OPG production, as well as calcium and phosphate content in cultured human osteoblasts. High concentration of TZDs (20 μM) enhances FGF-23 production. RANKL synthesis is not affected by TZDs. Thus, TZDs not only induce adipogenesis, but also affect the mineral content and the components of the Wnt signaling pathway in human osteoblasts.
Nothing to Disclose: YH, NB, VS, AKS, ASP, YKL, LP, DLTS
*Please take note of The Endocrine Society's News Embargo Policy at http://www.endo-society.org/endo2013/media.cfm
See more of: Abstracts - Orals, Featured Poster Presentations, and Posters